2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 113 | - | - | ||
| 83 | - | - | ||
| 66 | - | - | ||
| 7 | - | - | ||
| 26 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·35 min sittenStatistics are a tough one.... Danish companies exported for 202 billion kroner in July and Jyllands-Posten almost cheers: New figures confirm: Things are going incredibly well in Denmark - and this time it's not Novo's fault... It could look like perfect timing. While the Danish pharmaceutical industry, led by Novo Nordisk, shows signs of a slowdown, the tailwind is palpable elsewhere... So Jyllands-Posten writes. I google export distributed by sectors and get the Ministry of Business: "The pharmaceutical industry (life science) continues to be the absolute main engine of the Danish economy. Recent figures from the Ministry of Business confirm that the pharmaceutical sector now accounts for a full 22 percent of total Danish goods exports." ... Yes, and a large company in that category has even increased their production abroad....
But you don't know if 22% is more or less than before? Looking at Danmarks Statistik's figures, JP is not wrong in saying that it hasn't been Novo that has driven the overall export growth lately. The category that medicine falls under hit a preliminary peak in June 2025 with exports of 22.7 billion kr. In July 2026, it was 20.8 billion kr., which was marginally higher than June 2026, but thus lower than the year before. Of course, we don't know how much of the total category ("Chemicals including medicinal products") consists of Novo's exports, and yes, they increasingly have production abroad, but still...
·42 min sittenShouldn't we just remember the Q1 and Q2 upward revisions that tell us that everything is shaping up to be better than expected 😁 There is so much sadness among the amateurs in here (we must assume that most are, without offending anyone)
I am not surprised by the development, it's somewhat as I expected it after the excellent financial report. With the prospect of several months without special news, I saw the stock fall to 280, that was my thought. Yes, there is some small good news but nothing that can turn the tide. I still believe the year will end in a small plus on revenue and profit, 1-2%. The direction is there and the price will also rise if my prediction comes true.
·1 t sittenNow that the stock is down anyway, why can't it just fall all the way to 200, for crying out loud. Then one can buy a proper load of shares and get the average price thoroughly shaved.There are probably not many, when it comes down to it, who want to sell lower than current.. The buyers are lurking around the corner..
·1 t sittenMy bid for today's close and what it will signal technically: 292+ kr.: Very positive. Today's fall has largely been rejected, and the 288-area is starting to look like a bottom. 290–292 kr.: Approved. Buyers have entered at the low levels, and the risk of further decline is reduced. 288–290 kr.: Acceptable, but still weak. Support is holding for now, but a proper reversal signal is missing. 285,5–288 kr.: Concerning. We close close to support without any significant reaction from buyers. Under 285,5 kr.: Negative. Support has been broken on a closing basis, and the risk of a test of 280–282 kr. increases. RSI is already around 28 and thus oversold. Therefore, what will be interesting today is whether buyers actually react to it. Personally, I would like to see a close above 290 – and preferably 292+.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |
2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sittenStatistics are a tough one.... Danish companies exported for 202 billion kroner in July and Jyllands-Posten almost cheers: New figures confirm: Things are going incredibly well in Denmark - and this time it's not Novo's fault... It could look like perfect timing. While the Danish pharmaceutical industry, led by Novo Nordisk, shows signs of a slowdown, the tailwind is palpable elsewhere... So Jyllands-Posten writes. I google export distributed by sectors and get the Ministry of Business: "The pharmaceutical industry (life science) continues to be the absolute main engine of the Danish economy. Recent figures from the Ministry of Business confirm that the pharmaceutical sector now accounts for a full 22 percent of total Danish goods exports." ... Yes, and a large company in that category has even increased their production abroad....But you don't know if 22% is more or less than before? Looking at Danmarks Statistik's figures, JP is not wrong in saying that it hasn't been Novo that has driven the overall export growth lately. The category that medicine falls under hit a preliminary peak in June 2025 with exports of 22.7 billion kr. In July 2026, it was 20.8 billion kr., which was marginally higher than June 2026, but thus lower than the year before. Of course, we don't know how much of the total category ("Chemicals including medicinal products") consists of Novo's exports, and yes, they increasingly have production abroad, but still...
- ·42 min sittenShouldn't we just remember the Q1 and Q2 upward revisions that tell us that everything is shaping up to be better than expected 😁 There is so much sadness among the amateurs in here (we must assume that most are, without offending anyone)I am not surprised by the development, it's somewhat as I expected it after the excellent financial report. With the prospect of several months without special news, I saw the stock fall to 280, that was my thought. Yes, there is some small good news but nothing that can turn the tide. I still believe the year will end in a small plus on revenue and profit, 1-2%. The direction is there and the price will also rise if my prediction comes true.
- ·1 t sittenNow that the stock is down anyway, why can't it just fall all the way to 200, for crying out loud. Then one can buy a proper load of shares and get the average price thoroughly shaved.There are probably not many, when it comes down to it, who want to sell lower than current.. The buyers are lurking around the corner..
- ·1 t sittenMy bid for today's close and what it will signal technically: 292+ kr.: Very positive. Today's fall has largely been rejected, and the 288-area is starting to look like a bottom. 290–292 kr.: Approved. Buyers have entered at the low levels, and the risk of further decline is reduced. 288–290 kr.: Acceptable, but still weak. Support is holding for now, but a proper reversal signal is missing. 285,5–288 kr.: Concerning. We close close to support without any significant reaction from buyers. Under 285,5 kr.: Negative. Support has been broken on a closing basis, and the risk of a test of 280–282 kr. increases. RSI is already around 28 and thus oversold. Therefore, what will be interesting today is whether buyers actually react to it. Personally, I would like to see a close above 290 – and preferably 292+.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 113 | - | - | ||
| 83 | - | - | ||
| 66 | - | - | ||
| 7 | - | - | ||
| 26 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |
2026 Q2 -tulosraportti
35 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,91%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sittenStatistics are a tough one.... Danish companies exported for 202 billion kroner in July and Jyllands-Posten almost cheers: New figures confirm: Things are going incredibly well in Denmark - and this time it's not Novo's fault... It could look like perfect timing. While the Danish pharmaceutical industry, led by Novo Nordisk, shows signs of a slowdown, the tailwind is palpable elsewhere... So Jyllands-Posten writes. I google export distributed by sectors and get the Ministry of Business: "The pharmaceutical industry (life science) continues to be the absolute main engine of the Danish economy. Recent figures from the Ministry of Business confirm that the pharmaceutical sector now accounts for a full 22 percent of total Danish goods exports." ... Yes, and a large company in that category has even increased their production abroad....But you don't know if 22% is more or less than before? Looking at Danmarks Statistik's figures, JP is not wrong in saying that it hasn't been Novo that has driven the overall export growth lately. The category that medicine falls under hit a preliminary peak in June 2025 with exports of 22.7 billion kr. In July 2026, it was 20.8 billion kr., which was marginally higher than June 2026, but thus lower than the year before. Of course, we don't know how much of the total category ("Chemicals including medicinal products") consists of Novo's exports, and yes, they increasingly have production abroad, but still...
- ·42 min sittenShouldn't we just remember the Q1 and Q2 upward revisions that tell us that everything is shaping up to be better than expected 😁 There is so much sadness among the amateurs in here (we must assume that most are, without offending anyone)I am not surprised by the development, it's somewhat as I expected it after the excellent financial report. With the prospect of several months without special news, I saw the stock fall to 280, that was my thought. Yes, there is some small good news but nothing that can turn the tide. I still believe the year will end in a small plus on revenue and profit, 1-2%. The direction is there and the price will also rise if my prediction comes true.
- ·1 t sittenNow that the stock is down anyway, why can't it just fall all the way to 200, for crying out loud. Then one can buy a proper load of shares and get the average price thoroughly shaved.There are probably not many, when it comes down to it, who want to sell lower than current.. The buyers are lurking around the corner..
- ·1 t sittenMy bid for today's close and what it will signal technically: 292+ kr.: Very positive. Today's fall has largely been rejected, and the 288-area is starting to look like a bottom. 290–292 kr.: Approved. Buyers have entered at the low levels, and the risk of further decline is reduced. 288–290 kr.: Acceptable, but still weak. Support is holding for now, but a proper reversal signal is missing. 285,5–288 kr.: Concerning. We close close to support without any significant reaction from buyers. Under 285,5 kr.: Negative. Support has been broken on a closing basis, and the risk of a test of 280–282 kr. increases. RSI is already around 28 and thus oversold. Therefore, what will be interesting today is whether buyers actually react to it. Personally, I would like to see a close above 290 – and preferably 292+.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 113 | - | - | ||
| 83 | - | - | ||
| 66 | - | - | ||
| 7 | - | - | ||
| 26 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 651 938 | 1 651 938 | 0 | 0 |